Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 329 (ZNF329) is a member of the zinc finger protein family, which consists of diverse transcription factors characterized by the presence of zinc finger domains capable of binding DNA and regulating gene expression. ZNF329 is predicted to function as a DNA-binding transcription activator, interacting with RNA polymerase II cis-regulatory regions to modulate transcription. There is currently limited information on the tissue-specific expression, physiological roles, or implications in disease for ZNF329. Unlike some other zinc finger proteins, ZNF329 has not been directly implicated in specific pathologies nor identified as a direct therapeutic target. The zinc finger family as a whole participates in cell proliferation, differentiation, apoptosis, and diverse regulatory pathways in health and disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein 329 (ZNF329).